Mainstream

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Post ContentxgnRead More

You might also be interested in reading Acuity Trading, Kira Financial, Eightcap, and More: Executive Moves of the Week.

July 29, 2025
In Mainstream